Generalized Anxiety Disorder Clinical Trial
Official title:
Challenging Uncertainty: Behavioural Experiments in the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD) is an anxiety disorder characterized by excessive and uncontrollable worry. Our research group has developed a cognitive-behavioural treatment (CBT) for GAD centered upon intolerance of uncertainty, a dispositional characteristic that arises from a set of negative beliefs about uncertainty and its consequences (Dugas & Robichaud, 2007). This CBT protocol has demonstrated good efficacy over four previous clinical trials: approximately 70% of participants fully remit from GAD following treatment and maintain these gains over extended follow-up periods. These results, while positive, do suggest that a substantial minority of individuals do not fully benefit from the existing treatment protocol. Across our randomized clinical trials, individuals who do not achieve diagnostic remission of GAD continue to endorse elevated levels of intolerance of uncertainty. This suggests that the current CBT protocol does not effectively reduce intolerance of uncertainty in some treated individuals. To address this, we have developed a modified version of the original CBT protocol that targets intolerance of uncertainty more directly. The goal of the current proposal is to determine whether this newly developed CBT protocol with fewer components can deliver comparable or superior GAD symptom reduction. A total of 7 participants with a primary diagnosis of GAD received the newly developed CBT protocol over 12 weekly sessions. Measures of GAD symptoms, psychopathology, and intolerance of uncertainty were administered at pre-, mid-, and post-treatment, as well as at 3- and 6-month follow-ups. The proposed study will provide information about the efficacy of this new CBT protocol in reducing GAD symptoms.
Generalized anxiety disorder (GAD) is characterized by excessive and uncontrollable worry
and anxiety. This common and debilitating anxiety disorder is associated with significant
distress as well as substantial impairment in occupational, social, and daily functioning.
As a result, effective treatment for GAD is essential. Several cognitive-behavioural
treatment (CBT) protocols have been developed for GAD, including an efficacious treatment
developed by our research group. This CBT protocol for GAD centres upon intolerance of
uncertainty, a dispositional characteristic that arises from a set of negative beliefs about
uncertainty and its consequences (Dugas & Robichaud, 2007). Previous research has shown that
individuals with GAD demonstrate high intolerance of uncertainty, and that there are a
number of potential pathways by which intolerance of uncertainty may lead to symptoms of GAD
(see Dugas & Robichaud, 2007 for a review). Our CBT protocol targeting intolerance of
uncertainty has demonstrated good efficacy across four published randomized clinical trials:
approximately 70% of participants have fully remitted from GAD following treatment and have
maintained these gains over extended follow-up periods. These results, while positive, do
suggest that a substantial minority of individuals do not fully benefit from the existing
treatment protocol. Across our randomized clinical trials, individuals who do not achieve
diagnostic remission of GAD continue to endorse elevated levels of intolerance of
uncertainty. This suggests that the current CBT protocol does not effectively reduce
intolerance of uncertainty in some treated individuals. Additionally, the existing treatment
protocol has 6 major components, utilizes a number of cognitive and behavioural techniques
(including symptom monitoring, motivational interviewing, situational exposure,
problem-solving training, and imaginal exposure), and requires at least 14 sessions to
implement. Recent literature (e.g., Cougle et al., 2011) has suggested that there is
increased need for parsimony and efficiency in CBT protocols. As a result, our research
group is investigating new methods of targeting intolerance of uncertainty that demonstrate
greater parsimony and efficiency.
Our previous CBT protocol for GAD targeted intolerance of uncertainty directly through
situational exposure, and indirectly through motivational interviewing, problem-solving
training, and imaginal exposure. In an effort to streamline and strengthen GAD treatment,
the newly developed CBT protocol only targets intolerance of uncertainty directly. In this
new CBT protocol, intolerance of uncertainty was targeted using behavioural experiments in
which participants identified and tested out their beliefs about uncertainty. The extant
literature suggests that behavioural experiments are an efficacious way to target the
emotional, cognitive, and behavioural components of anxiety disorders and may be superior to
habituation-based exposure paradigms (McMillan & Lee, 2010; Salkovskis et al., 2007).
The current study examined if a newly developed CBT protocol with fewer components could
deliver comparable GAD symptom reduction. Seven (7) individuals with a primary diagnosis of
GAD completed 12 sessions of CBT using a newly developed treatment protocol focusing
exclusively on intolerance of uncertainty. The treatment consisted of 50-minute, weekly
sessions targeting intolerance of uncertainty primarily via behavioural experiments. The
three treatment components included: (1) psychoeducation and uncertainty awareness training;
(2) testing beliefs about uncertainty (via behavioural experiments); and (3) relapse
prevention. Measures of GAD symptoms, general psychopathology, and intolerance of
uncertainty were administered at pre-, mid-, and post-treatment, as well as at 3- and
6-month follow-ups. Our main outcomes of interest were effect sizes (i.e., relative
magnitude of change from pre-posttreatment, pretreatment to 6-month follow-up, and
posttreatment to 6-month follow-up).
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00620776 -
Combined Treatment for Generalized Anxiety Disorder (GAD)
|
Phase 2 | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |